

**DECLARATION AND POWER OF ATTORNEY FOR
UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,
and

I believe that I am the original, first and sole inventor (if only one name is listed below)
or an original, first and joint inventor (if more than one name is listed below) of the subject
matter which is claimed and for which a United States patent is sought on the invention entitled

HUMAN LYSOPHOSPHOLIPASE

the specification of which:

 / is attached hereto.

/ X / was filed on April 29, 1997 as application Serial No. 08/844,120 and
if this box contains an X /, was amended on .

/ / was filed as Patent Cooperation Treaty international application No. on
 , 19 , if this box contains an X / /, was amended on under Patent Cooperation
Treaty Article 19 on 19 , and if this box contains an X / /, was amended on .

I hereby state that I have reviewed and understand the contents of the above-identified
specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of
this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any
foreign application(s) for patent or inventor's certificate indicated below and of any Patent
Cooperation Treaty international applications(s) designating at least one country other than the
United States indicated below and have also identified below any foreign application(s) for patent
or inventor's certificate and Patent Cooperation Treaty international application(s) designating at
least one country other than the United States for the same subject matter and having a filing date
before that of the application for said subject matter the priority of which is claimed:

Country	Number	Filing Date	Priority Claimed
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application	Status (Pending, Abandoned, Patented)
Serial No. _____ Filed _____	_____

I hereby appoint the following:

LUCY J. BILLINGS
MICHAEL C. CERRONE

Registration No. 36,749
Registration No. 39,132

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

LUCY J. BILLINGS, ESQ.
INCYTE PHARMACEUTICALS, INC.
3174 PORTER DRIVE, PALO ALTO, CA 94304

TEL: 650-855-0555 FAX: 650-845-4166


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


***IMPORTANT:** Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Sole Inventor or

First Joint Inventor:

Full name: **JENNIFER L. HILLMAN**
Signature: 
Date: 10/20/97 . 1997
Citizenship: United States of America
Residence: Mountain View, California
P.O. Address: 230 Monroe Drive, #12
Mountain View, California

Second Joint Inventor:

Full name: **PURVI SHAH**
Signature: 
Date: 10/20 . 1997
Citizenship: India
Residence: Sunnyvale, California
P.O. Address: 1608 Queen Charlotte Drive, #5
Sunnyvale, California, 94087

Third Joint Inventor:

Full name:

LYNN E. MURRY

Signature:

Lynn E. Murry

Date:

21 October, 1997

Citizenship:

United States of America

Residence:

Portola Valley, California

P.O. Address:

1124 Los Trancos Road
Portola Valley, California, 94028

2025 OCT 21 10 00 AM

"Express Mail" mailing label number EL 856 173 600 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, 2900 Crystal Dr., Arlington, VA 22202-3513 on November 19, 2001

By: _____

Printed: Nancy Ramos**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Hillman, et al.

Title: HUMAN LYSOPHOSPHOLIPASE

Serial No.: To Be Assigned

Filing Date:

Herewith

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

Commissioner for Patents
Box Patent Application
2900 Crystal Dr.
Arlington, VA 22202-3513

**CERTIFICATE UNDER 37 C.F.R. §3.73(b),
REVOCATION OF POWER OF ATTORNEY AND
APPOINTMENT OF NEW ATTORNEYS**

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Genomics, Inc., formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8818, Frame 0909, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Lucy J. Billings	Reg. No. 36,749
Jenny Buchbinder	Reg. No. 48,588
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Richard C. Ekstrom	Reg. No. 37,027
Barrie D. Greene	Reg. No. 46,740
Lynn E. Murry	Reg. No. 42,918
Shirley A. Recipon	Reg. No. 47,016
Cathleen M. Rocco	Reg. No. 46,172
Susan K. Sather	Reg. No. 44,316
Michelle M. Stempien	Reg. No. 41,327
David G. Streeter	Reg. No. 43,168
Sreenivasarao Vepachedu	Reg. No. 46,395

Please direct all correspondence to:

Legal Department
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, California 94304


and direct all telephone calls and facsimile transmissions to: Diana Hamlet-Cox, Incyte Genomics, Inc.,
Phone: (650) 845-4639, Fax: (650) 849-8886 or (650) 845-4166.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE GENOMICS, INC.

Date: November 19, 2001

By: 
Lee Bendekgey
VP, General Counsel/Corporate Secretary

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Hillman, Jennifer L.
Shah, Purvi
Murry, Lynn E.
- (ii) TITLE OF THE INVENTION: HUMAN LYSOPHOSPHOLIPASE
- (iii) NUMBER OF SEQUENCES: 3
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 - (B) STREET: 3174 Porter Drive
 - (C) CITY: Palo Alto
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: Filed Herewith
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Billings, Lucy J.
 - (B) REGISTRATION NUMBER: 36,749
 - (C) REFERENCE/DOCKET NUMBER: PF-0269 US
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 415-855-0555
 - (B) TELEFAX: 415-845-4166

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 208 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY: KIDNNOT19
 - (B) CLONE: 2676650

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met	Cys	Gly	Asn	Asn	Met	Ser	Thr	Pro	Leu	Pro	Ala	Ile	Val	Pro	Ala
1				5				10					15		
Ala	Arg	Lys	Ala	Thr	Ala	Ala	Val	Ile	Phe	Leu	His	Gly	Leu	Gly	Asp
		20						25					30		
Thr	Gly	Pro	Val	Arg	Pro	Val	Thr	Leu	Asn	Met	Asn	Val	Ala	Met	Pro
		35					40						45		

```

Ser Trp Phe Asp Ile Ile Gly Leu Ser Pro Asp Ser Gln Glu Asp Glu
 50          55          60
Ser Gly Ile Lys Gln Ala Ala Glu Asn Ile Lys Ala Leu Ile Asp Gln
65          70          75          80
Glu Val Lys Asn Gly Ile Pro Ser Asn Arg Ile Ile Leu Gly Gly Phe
      85          90          95
Ser Gln Gly Gly Ala Leu Ser Leu Tyr Thr Ala Leu Thr Thr Gln Gln
      100          105          110
Lys Leu Ala Gly Val Thr Ala Leu Ser Phe Leu Leu Pro Leu Arg Xaa
      115          120          125
Ser Phe Pro Gln Gly Pro Ile Gly Gly Ala Asn Arg Asp Ile Ser Ile
      130          135          140
Leu Gln Cys His Gly Asp Cys Asp Pro Leu Val Pro Leu Met Phe Gly
145          150          155          160
Ser Leu Thr Val Glu Lys Leu Lys Thr Leu Val Asn Pro Ala Asn Val
      165          170          175
Thr Phe Lys Thr Tyr Glu Gly Met Met His Ser Ser Cys Gln Gln Glu
      180          185          190
Met Met Asp Val Lys Gln Phe Ile Asp Lys Leu Leu Pro Pro Ile Asp
      195          200          205

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 709 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: KIDNNOT19
- (B) CLONE: 2676650

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

GCCGCTCGCA CGCCCTTGGG CCGCGGCCGG GCGCCCGCTC TTCCTTCCGC TTGCGCTGTG      60
AGCTGAGGCG GTGTATGTGC GGCAATAACA TGTCAACCCC GCTGCCCCGC ATCGTGCCCCG      120
CCGCCCCGAA GGCCACCGCT GCGGTGATTT TCCTGCATGG ATTGGGAGAT ACTGGGCCTG      180
TTAGGCCTGT TACATTAAAT ATGAACGTGG CTATGCCTTC ATGGTTTGAT ATTATTGGGC      240
TTTCACCAGA TTCACAGGAG GATGAATCTG GGATTAAACA GGCAGCAGAA AATATAAAAG      300
CTTTGATTGA TCAAGAAGTG AAGAATGGCA TTCCTTCTAA CAGAATTATT TTGGGAGGGT      360
TTTCTCAGGG AGGAGCTTTA TCTTTATATA CTGCCCTTAC CACACAGCAG AAACCTGGCAG      420
GTGTCACTGC ACTCAGTTTC TTGCTTCCAC TTCGGGNTTC CTTTCCACAG GKKCCTATCG      480
GTGGTGCTAA TAGAGATATT TCTATTCTCC AGTGCCACGG GGATTGTGAC CCTTTGGTTC      540
CCCTGATGTT TGGTTCTCTT ACGGTGGAAA AACTAAAAC ATTGGTGAAT CCAGCCAATG      600
TGACCTTTAA AACCTATGAA GGTATGATGC ACAGTTCGTG TCAACAGGAA ATGATGGATG      660
TCAAGCAATT CATTGATAAA CTCCTACCTC CAATTGATTG ACGTCACTA      709

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 230 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 1552244

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met	Cys	Gly	Asn	Asn	Met	Ser	Ala	Pro	Met	Pro	Ala	Val	Val	Pro	Ala
1				5					10					15	
Ala	Arg	Lys	Ala	Thr	Ala	Ala	Val	Ile	Phe	Leu	His	Gly	Leu	Gly	Asp
			20					25					30		
Thr	Gly	His	Gly	Trp	Ala	Glu	Ala	Phe	Ala	Gly	Ile	Lys	Ser	Ser	His
		35					40					45			
Ile	Lys	Tyr	Ile	Cys	Pro	His	Ala	Pro	Val	Met	Pro	Val	Thr	Leu	Asn
	50					55					60				
Met	Ser	Met	Met	Met	Pro	Ser	Trp	Phe	Asp	Ile	Ile	Gly	Leu	Ser	Pro
65					70				75					80	
Asp	Ser	Gln	Glu	Asp	Glu	Ser	Gly	Ile	Lys	Gln	Ala	Ala	Glu	Thr	Val
			85					90					95		
Lys	Ala	Leu	Ile	Asp	Gln	Glu	Val	Lys	Asn	Gly	Ile	Pro	Ser	Asn	Arg
			100					105					110		
Ile	Ile	Leu	Gly	Gly	Phe	Ser	Gln	Gly	Gly	Ala	Leu	Ser	Leu	Tyr	Thr
		115					120					125			
Ala	Leu	Thr	Thr	Gln	Gln	Lys	Leu	Ala	Gly	Val	Thr	Ala	Leu	Ser	Cys
	130					135					140				
Trp	Leu	Pro	Leu	Arg	Ala	Ser	Phe	Ser	Gln	Gly	Pro	Ile	Asn	Ser	Ala
145					150				155					160	
Asn	Arg	Asp	Ile	Ser	Val	Leu	Gln	Cys	His	Gly	Asp	Cys	Asp	Pro	Leu
			165					170					175		
Val	Pro	Leu	Met	Phe	Gly	Ser	Leu	Thr	Val	Glu	Arg	Leu	Lys	Gly	Leu
			180					185					190		
Val	Asn	Pro	Ala	Asn	Val	Thr	Phe	Lys	Val	Tyr	Glu	Gly	Met	Met	His
		195				200						205			
Ser	Ser	Cys	Gln	Gln	Glu	Met	Met	Asp	Val	Lys	Tyr	Phe	Ile	Asp	Lys
	210					215					220				
Leu	Leu	Pro	Pro	Ile	Asp										
225					230										